Fibrillarin-autoantibodies
Material: | 1 ml serum |
Methods: | Ligandenassays → Immunfluoreszenzassay (IFA) | Reference range | < 1:100 titer |
Indication | Suspicion of early onset scleroderma |
Please note | Fibrillarin is a component of the extractable nuclear antigens (ENA). Antibodies against fibrillarin are often detected in case of early onset acroscleroderma or diffuse scleroderma. They are rarely seen in combination with other marker autoantibodies. |
External services | ja Klinisch-immunologisches Labor Dr. Stöcker |
More Results for the letter F
- Factor II activity (FACT01)
- Prothrombin
- Factor II mutation (FACT02)
- Prothrombin mutation G20210A
- Factor IX activity (FACT11)
- Factor V activity (FACT03)
- Factor V mutation Leiden (FACT04)
- Mutation: G1691A
- Factor VII activity (FACT05)
- Factor VIII activity (FACT06)
- Factor VIII inhibitor (FACT10)
- Factor VIII ristocetin cofactor (von Willebrand factor activity) (FACT08)
- vWF:activity
- Factor VIII von Willebrand factor antigen (FACT07)
- vWF:Ag
- Factor VIII von Willebrand multimers (FACT09)
- Factor X activity (FACT12)
- Factor XI activity (FACT13)
- Factor XII activity (FACT14)
- Hageman-Factor
- Factor XIII activity (FACT15)
- Syn.: fibrin stabilising factor
- Factor–II–activity (FAK2)
- Prothrombin
- Factor-II-mutation (FAK2GM)
- Prothrombin mutation G20210A
- Factor-IX-activity (FAK9)
- Factor-V-activity (FAK5)
- Factor-V-mutation Leiden (FAK5GM)
- Mutation: G1691A
- Factor-VII-activity (FAK7)
- Factor-VIII-activity (FAK8)
- Factor-VIII-inhibitor (FAK8IN)
- Bethesda assay
- Factor-X-activity (FAK10)
- Factor-XI-activity (FAK11)
- Factor-XII-activity (FAK12)
- Hageman factor
- Factor-XIII-activity (FAK13)
- Fibrin-stabilizing factor
- Fasciola hepatica (FASCI, FASCG)
- Common liver fluke
- Fat, total in stool (FETT1)
- Fatty acids, long-chained (LAFS)
- LCFA